Cramer On Housing Stock: 'No One's Buying Homes Here' - Netflix ( NASDAQ:NFLX ) , FuboTV ( NYSE:FUBO )
On CNBC's "Mad Money Lightning Round," on Thursday, Jim Cramer said he prefers Netflix, Inc. ( NASDAQ:NFLX ) over fuboTV Inc. ( NYSE:FUBO ) . FuboTV reported earnings for the third quarter of 2025 on Nov. 3.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Regeneron Pharmaceuticals ( NASDAQ:REGN )
On Wednesday, the U.S. Food and Drug Administration ( FDA ) approved Regeneron Pharmaceuticals Inc.'s ( NASDAQ:REGN ) Eylea HD ( aflibercept ) Injection 8 mg for patients with macular edema following retinal vein occlusion ( RVO ) with up to every 8-week dosing after an initial monthly dosing ...
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
EYLEA HD® ( aflibercept ) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion ( RVO ) and for Monthly Dosing Across Approved Indications
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period ...
EYLEA HD® ( aflibercept ) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion ( RVO ) and for Monthly Dosing Across Approved Indications - Regeneron Pharmaceuticals ( NASDAQ:REGN )
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period TARRYTOWN, N.Y., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) today announced that the U.S.
Libtayo® ( cemiplimab ) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma ( CSCC ) with High Risk of Recurrence after Surgery and Radiation - Regeneron Pharmaceuticals ( NASDAQ:REGN )
TARRYTOWN, N.Y., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) today announced that the European Commission ( EC ) has approved the PD-1 inhibitor Libtayo® ( cemiplimab ) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma ( ...
2 Beaten-Down Stocks to Avoid Right Now
There might be plenty more downside for these biotechs.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Cathie Dumps AMD And Reddit Shares Amid Tech Bloodbath, Ark Doubles Down On Tom Lee And Peter Thiel Crypto Plays - Advanced Micro Devices ( NASDAQ:AMD )
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably involving Circle Internet Group Inc ( NYSE:CRCL ) , Bitmine Immersion Technologies Inc ( NYSE:BMNR ) , Bullish ( NYSE:BLSH ) , Advanced Micro Devices Inc ( NASDAQ:AMD ) , and Reddit Inc ( NYSE:RDDT ) .
Regeneron Highlights Progress at American Society of Hematology ( ASH ) , with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
Oral presentation of Lynozyfic™ ( linvoseltamab-gcpt ) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting ...
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know
These top growth stocks have plenty of room left to run.
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, November 12, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and provided a summary ...
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and ...
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial - CRISPR Therapeutics ( NASDAQ:CRSP )
On Saturday, CRISPR Therapeutics AG ( NASDAQ:CRSP ) shared Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran ( nex-z ) in Patients with Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy - Intellia Therapeutics ( NASDAQ:NTLA )
One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baseline
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran ( nex-z ) in Patients with Transthyretin ( ATTR ) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive follow-up data from the ongoing Phase 1 clinical trial of ...
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® ( aflibercept )
REYKJAVIK, ICELAND ( November 10, 2025 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron ...
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® ( aflibercept )
REYKJAVIK, Iceland, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court ...
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® ( aflibercept ) - Alvotech ( NASDAQ:ALVO )
REYKJAVIK, Iceland, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ:ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court ...
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Trial results consistent with prospective design of these antibodies to have distinct profiles - one to provide stronger anticoagulation and the other to have a lower risk of bleeding - potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron's two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement ...
6 of the best: the billion-dollar biotechs putting China on the map
The ferocity of China's biopharmaceutical investment boom this year - fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump - may have surprised casual observers. But according to Helen Chen, one of the most respected analysts and advisers in China's ...
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Wall Street may be overestimating these companies' potential.
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis. sBLA accepted for FDA priority review ...
Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - Regeneron Pharmaceuticals ( NASDAQ:REGN )
ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals ( NASDAQ:REGN ) has outperformed the market over the past 20 years by 13.72% on an annualized basis producing an average annual return of 22.58%. Currently, Regeneron Pharmaceuticals has a market capitalization of $67.34 billion.
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals Inc's ( NYSE:REGN ) short interest as a percent of float has risen 5.93% since its last report. According to exchange reported data, there are now 2.93 million shares sold short, which is 2.86% of all regular shares that are available for trading.
Michael Burry Is Super-Bearish On Palantir - With 5 Million Puts - Palantir Technologies ( NASDAQ:PLTR )
A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. ( NASDAQ:PLTR ) and one million put options on NVIDIA Corp. ( NASDAQ:NVDA ) , among other changes to its portfolio.
2 Beaten-Down Stocks That Could Be About to Rally
It would be best to get in before the rest of the market pounces on these opportunities.
BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update
BioNTech SE today reported financial results for the three and nine months ended September 30, 2025 and provide an update on its corporate progress.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
Maybe Cathie Wood and Wall Street are being too optimistic.
Dupixent® ( dupilumab ) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...
Regeneron ( REGN ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Oct. 28, 2025, 8:30 a.m. ETBoard Co-Chair, Co-Founder, President, and Chief Executive Officer - Dr. Leonard SchleiferContinue reading ...
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: Markets Today - American Tower ( NYSE:AMT ) , Ares Capital ( NASDAQ:ARCC )
Tech stocks are extending their rally into a fourth straight session on Tuesday, with the Nasdaq 100 climbing 0.7% by midday to reach a new record high of 26,000 points, as optimism builds ahead of key earnings and a widely expected Federal Reserve rate cut.
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Agilysys ( NASDAQ:AGYS )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Tuesday. Shares of Wayfair Inc ( NYSE:W ) rose sharply during Tuesday's session following better-than-expected third-quarter results.
Exploring Analyst Estimates for Alnylam ( ALNY ) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals Inc. ( NASDAQ:REGN ) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59. The company reported sales of $3.75 billion, up 1% year over year, beating the consensus of $3.59 billion.
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
- ARCALYST® ( rilonacept ) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387 granted Orphan Drug Designation for the treatment of pericarditis - - Cash balance increased by ...
Regeneron Reports Third Quarter 2025 Financial and Operating Results
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent® global net sales ( recorded by Sanofi ) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion
Regeneron Reports Third Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the third quarter of 2025 and provided a business update.
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran ( nex-z )
Conference call today at 8:30 a.m. ET Conference call today at 8:30 a.m. ET ...
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals ( NASDAQ:REGN )
Regeneron Pharmaceuticals ( NASDAQ:REGN ) has outperformed the market over the past 20 years by 12.6% on an annualized basis producing an average annual return of 21.67%. Currently, Regeneron Pharmaceuticals has a market capitalization of $62.41 billion.
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
FDA Unveils Fast-Track Drugs to Slash Review Times - Disc Medicine ( NASDAQ:IRON )
The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times ...
